As TIMP3 is a tumor suppressor frequently found downregulated in prostate cancer, our work is of clinical relevance, which may lead to a new approach in interrupting prostate cancer development and invasion by targeting miR-17 expression. Here, TIMP3 is linked to neoplasm.